Analysts predict that Harvard Bioscience, Inc. (NASDAQ:HBIO – Get Rating) will report earnings per share (EPS) of $0.05 for the current quarter, Zacks Investment Research reports. Two analysts have made estimates for Harvard Bioscience’s earnings. Harvard Bioscience also posted earnings of $0.05 per share in the same quarter last year. The business is expected to announce its next quarterly earnings results on Monday, January 1st.
On average, analysts expect that Harvard Bioscience will report full year earnings of $0.32 per share for the current financial year. For the next fiscal year, analysts anticipate that the company will report earnings of $0.40 per share. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side research analysts that cover Harvard Bioscience.
Harvard Bioscience (NASDAQ:HBIO – Get Rating) last issued its quarterly earnings results on Tuesday, March 8th. The medical instruments supplier reported $0.06 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.07 by ($0.01). The business had revenue of $33.06 million for the quarter, compared to analyst estimates of $32.65 million. Harvard Bioscience had a positive return on equity of 9.78% and a negative net margin of 0.24%. During the same quarter in the previous year, the business posted $0.06 earnings per share.
Shares of HBIO opened at $6.21 on Friday. The firm has a market cap of $256.04 million, a P/E ratio of -621.00 and a beta of 1.85. The company has a debt-to-equity ratio of 0.54, a quick ratio of 1.34 and a current ratio of 2.43. Harvard Bioscience has a one year low of $5.00 and a one year high of $8.75. The company has a 50-day moving average price of $5.85.
Several institutional investors have recently bought and sold shares of HBIO. Citigroup Inc. lifted its position in shares of Harvard Bioscience by 146.3% during the 3rd quarter. Citigroup Inc. now owns 4,512 shares of the medical instruments supplier’s stock worth $31,000 after buying an additional 2,680 shares in the last quarter. Royal Bank of Canada raised its holdings in shares of Harvard Bioscience by 47.6% in the 3rd quarter. Royal Bank of Canada now owns 4,452 shares of the medical instruments supplier’s stock worth $31,000 after purchasing an additional 1,435 shares during the period. Altshuler Shaham Ltd bought a new stake in shares of Harvard Bioscience in the 3rd quarter worth approximately $43,000. BNP Paribas Arbitrage SA raised its holdings in shares of Harvard Bioscience by 488.1% in the 3rd quarter. BNP Paribas Arbitrage SA now owns 7,551 shares of the medical instruments supplier’s stock worth $53,000 after purchasing an additional 6,267 shares during the period. Finally, Morgan Stanley raised its holdings in shares of Harvard Bioscience by 15.2% in the 3rd quarter. Morgan Stanley now owns 9,746 shares of the medical instruments supplier’s stock worth $69,000 after purchasing an additional 1,289 shares during the period. 70.40% of the stock is currently owned by hedge funds and other institutional investors.
Harvard Bioscience Company Profile (Get Rating)
Harvard Bioscience, Inc develops, manufactures, and sells technologies, products, and services that enables fundamental research, discovery, and pre-clinical testing for drug development in the United States and internationally. The company offers cellular and molecular technology instruments, such as syringe and peristaltic pump products, as well as a range of instruments and accessories for tissue and organ-based lab research, including surgical products, infusion systems, and behavior research systems; and spectrophotometers, microplate readers, amino acid analyzers, gel electrophoresis equipment, and electroporation and electrofusion instruments.
- Get a free copy of the StockNews.com research report on Harvard Bioscience (HBIO)
- 3 Best Recession-Resistant, Cost-Conscious Retail Stocks to Take a Look at Right Now
- 3 Tech Stocks to Buy for Retirement
- Schlumberger Analyst Coverage Drives Market Higher
- Simply Good Foods Stock is a Healthy Defensive Play
- Poor Timing Will Put Delta Air Lines on Standby For Risk-Off Investors
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Harvard Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harvard Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.